Physician profile
Amer Khouri
NPI 1205833084
$7,773.51
in general payments reported to CMS, 2019-2025
52 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,152 · 2020: $686 · 2021: $875 · 2022: $679 · 2023: $384 · 2024: $1,998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,364 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,363.68 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $2,452.56 | 2019-2024 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $449.95 | 2019-2024 | Opdualag, Augtyro, Opdivo |
| Novartis Pharmaceuticals Corporation | $399.46 | 2019-2024 | |
| Celgene Corporation | $289.42 | 2019-2024 | Reblozyl, Pomalyst |
| Janssen Biotech, INC. | $285.96 | 2019-2024 | Rybrevant, Imbruvica, Tecvayli |
| Genentech USA, INC. | $275.90 | 2019-2024 | Venclexta, Gazyva, Tecentriq |
| Merck Sharp & Dohme LLC | $260.66 | 2019-2024 | Keytruda, Lynparza, Reblozyl |
| Astrazeneca Pharmaceuticals Lp | $258.23 | 2019-2024 | Imfinzi, Enhertu |
| Pfizer INC. | $220.26 | 2019-2024 | |
| Genzyme Corporation | $204.87 | 2019-2024 | |
| Novocure Gmbh | $200.00 | 2022 | |
| Seagen INC. | $195.03 | 2019-2022 | |
| Astellas Pharma US INC | $184.36 | 2019-2024 | Xospata |
| Amgen INC. | $173.87 | 2019-2021 | |
| Pharmacyclics LLC, An Abbvie Company | $142.31 | 2020-2023 | Imbruvica |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amer Khouri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.